drugset / Trial / NCT00538798

PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

NCT00538798 ↗

Phase 1 Completed 50 enrolled National Institute of Mental Health (NIMH)
Treatment

Summary

The metabotropic glutamate subtype five (mGluR5) receptor is a protein found in the brain and is the target for the excitatory chemical messenger glutimate. The purpose of this protocol is to measure mGluR5 receptors in the brain using positron emission tomography (PET) and a research drug called \[18F\]SP203.

Timeline

Start
2007-09-28
Primary completion
—
Completion
2015-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]SP203 Diagnostic / imaging agent — —

Indications

No indication recorded.